NASDAQ:AMAG - AMAG Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$20.65 -0.25 (-1.20 %)
(As of 09/21/2018 04:00 PM ET)
Previous Close$20.65
Today's Range$20.45 - $21.2750
52-Week Range$11.93 - $26.10
Volume1.22 million shs
Average Volume496,022 shs
Market Capitalization$720.48 million
P/E Ratio-3.62
Dividend YieldN/A
Beta0.48
AMAG Pharmaceuticals logoAMAG Pharmaceuticals, Inc., a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. The company also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units for pregnant women and their families. In addition, it has an option agreement with Velo Bio LLC to acquire the rights to digoxin immune fab, a polyclonal antibody, which is in Phase IIb/IIIa trial for the treatment of severe preeclampsia in pregnant women. The company sells Feraheme to authorized wholesalers and specialty distributors. It has a license agreement with Palatin Technologies, Inc. to research, develop, and commercialize Bremelanotide, an investigational product for the treatment of hypoactive sexual desire disorder (HSDD) in pre-menopausal women, as well as with Endoceutics, Inc. to develop and commercialize pharmaceutical products with dehydroepiandrosterone; and development and license agreement with Antares Pharma, Inc. to develop, use, sell, offer for sale, and import and export the Makena auto-injector. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

Receive AMAG News and Ratings via Email

Sign-up to receive the latest news and ratings for AMAG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:AMAG
CUSIP00163U10
Phone617-498-3300

Debt

Debt-to-Equity Ratio0.99
Current Ratio2.06
Quick Ratio1.95

Price-To-Earnings

Trailing P/E Ratio-3.62
Forward P/E Ratio-6.02
P/E GrowthN/A

Sales & Book Value

Annual Sales$609.95 million
Price / Sales1.17
Cash FlowN/A
Price / CashN/A
Book Value$22.34 per share
Price / Book0.92

Profitability

EPS (Most Recent Fiscal Year)($5.71)
Net Income$-199,220,000.00
Net Margins-36.87%
Return on Equity-2.77%
Return on Assets-1.13%

Miscellaneous

Employees762
Outstanding Shares34,470,000
Market Cap$720.48 million

AMAG Pharmaceuticals (NASDAQ:AMAG) Frequently Asked Questions

What is AMAG Pharmaceuticals' stock symbol?

AMAG Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMAG."

How were AMAG Pharmaceuticals' earnings last quarter?

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) issued its earnings results on Thursday, August, 2nd. The specialty pharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.21) by $0.54. The specialty pharmaceutical company had revenue of $146.25 million for the quarter, compared to the consensus estimate of $156.26 million. AMAG Pharmaceuticals had a negative return on equity of 2.77% and a negative net margin of 36.87%. The firm's revenue was up 12.2% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.40) earnings per share. View AMAG Pharmaceuticals' Earnings History.

When is AMAG Pharmaceuticals' next earnings date?

AMAG Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, November, 1st 2018. View Earnings Estimates for AMAG Pharmaceuticals.

What price target have analysts set for AMAG?

9 brokers have issued 1 year price targets for AMAG Pharmaceuticals' stock. Their forecasts range from $18.00 to $31.00. On average, they expect AMAG Pharmaceuticals' stock price to reach $23.0722 in the next twelve months. This suggests a possible upside of 11.7% from the stock's current price. View Analyst Price Targets for AMAG Pharmaceuticals.

What is the consensus analysts' recommendation for AMAG Pharmaceuticals?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AMAG Pharmaceuticals in the last year. There are currently 7 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AMAG Pharmaceuticals.

What are Wall Street analysts saying about AMAG Pharmaceuticals stock?

Here are some recent quotes from research analysts about AMAG Pharmaceuticals stock:
  • 1. Cantor Fitzgerald analysts commented, ": We reiterate the Neutral rating and adjust our PT to $18 (from $17) for AMAG stock. With the commercial potential of Intrarosa still unproven and the approvability of bremelanotide unknown, we believe investors will view the Makena franchise as the most significant supporter of share price value, particularly now that the CBR business is being divested. We suppose a bullish outlook could prevail over the near- to intermediate-term if Makena holds its own and no evidence emerges that Intrarosa or bremelanotide could disappoint expectations. We believe that the set up for 2019 has to be decidedly positive for the stock to perform well over the next 12-18 months absent, of course, transformational business activities." (8/3/2018)
  • 2. According to Zacks Investment Research, "AMAG reported earnings of $1.57 in the third quarter of 2017 as against the Zacks Consensus Estimate of a loss. However, the company missed the same on revenues. AMAG lowered its total revenue guidance for 2017. Furthermore, the termination of the licensing agreement with Takeda for Feraheme in ex-U.S. territories was a major setback for the company. So far this year, AMAG’s shares have underperformed the industry.  Nevertheless, the company  is working towards label expansion of Feraheme, and potential approval and launch of the Makena subcutaneous auto-injector (SQ) AMAG also remains focused on expanding Makena’s label further in a bid to increase its market share." (11/8/2017)

Who are some of AMAG Pharmaceuticals' key competitors?

Who are AMAG Pharmaceuticals' key executives?

AMAG Pharmaceuticals' management team includes the folowing people:
  • Dr. William K. Heiden, CEO, Pres & Director (Age 58)
  • Mr. Edward H. Myles, Exec. VP & CFO (Age 46)
  • Mr. Joseph D. Vittiglio, Exec. VP of Legal Affairs and Quality, Gen. Counsel & Sec. (Age 46)
  • Dr. Julie Krop, Exec. VP of Devel. & Chief Medical Officer (Age 52)
  • Mr. Nicholas Grund, Exec. VP & Chief Commercial Officer (Age 48)

Who are AMAG Pharmaceuticals' major shareholders?

AMAG Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (5.78%), Renaissance Technologies LLC (4.76%), Russell Investments Group Ltd. (3.41%), Dimensional Fund Advisors LP (3.24%), Robeco Institutional Asset Management B.V. (2.84%) and Connor Clark & Lunn Investment Management Ltd. (1.84%). Company insiders that own AMAG Pharmaceuticals stock include Joseph Vittiglio, Julie Krop and William K Heiden. View Institutional Ownership Trends for AMAG Pharmaceuticals.

Which institutional investors are selling AMAG Pharmaceuticals stock?

AMAG stock was sold by a variety of institutional investors in the last quarter, including State Board of Administration of Florida Retirement System, Balter Liquid Alternatives LLC, Connor Clark & Lunn Investment Management Ltd., Spark Investment Management LLC, Dimensional Fund Advisors LP, Foundry Partners LLC, Pinebridge Investments L.P. and Systematic Financial Management LP. Company insiders that have sold AMAG Pharmaceuticals company stock in the last year include Joseph Vittiglio and William K Heiden. View Insider Buying and Selling for AMAG Pharmaceuticals.

Which institutional investors are buying AMAG Pharmaceuticals stock?

AMAG stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Macquarie Group Ltd., Sei Investments Co., Opaleye Management Inc., Acadian Asset Management LLC, Robeco Institutional Asset Management B.V., Russell Investments Group Ltd. and Renaissance Technologies LLC. View Insider Buying and Selling for AMAG Pharmaceuticals.

How do I buy shares of AMAG Pharmaceuticals?

Shares of AMAG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AMAG Pharmaceuticals' stock price today?

One share of AMAG stock can currently be purchased for approximately $20.65.

How big of a company is AMAG Pharmaceuticals?

AMAG Pharmaceuticals has a market capitalization of $720.48 million and generates $609.95 million in revenue each year. The specialty pharmaceutical company earns $-199,220,000.00 in net income (profit) each year or ($5.71) on an earnings per share basis. AMAG Pharmaceuticals employs 762 workers across the globe.

What is AMAG Pharmaceuticals' official website?

The official website for AMAG Pharmaceuticals is http://www.amagpharma.com.

How can I contact AMAG Pharmaceuticals?

AMAG Pharmaceuticals' mailing address is 1100 WINTER STREET, WALTHAM MA, 02451. The specialty pharmaceutical company can be reached via phone at 617-498-3300 or via email at [email protected]


MarketBeat Community Rating for AMAG Pharmaceuticals (NASDAQ AMAG)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  311 (Vote Outperform)
Underperform Votes:  398 (Vote Underperform)
Total Votes:  709
MarketBeat's community ratings are surveys of what our community members think about AMAG Pharmaceuticals and other stocks. Vote "Outperform" if you believe AMAG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMAG will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel